Development of novel antimicrobials has slowed, and the preclinical and clinical pipeline is likely to be insufficient to support current and future patient needs. Despite existing incentives, market challenges limit the revenues that novel antimicrobial drug sponsors can receive, leading smaller developers to struggle financially and larger companies to divest from antimicrobial research and development. Ongoing and future patient access to antimicrobial products can be supported alongside antibiotic stewardship goals through significant additional financial incentives that provide a predictable revenue stream for sponsors, particularly those that are “de-linked” from the volume of product sales.
*This content is in the process of Section 508 review. If you need immediate assistance accessing this content, please submit a request to Casey Sullivan, email@example.com. Content will be updated pending the outcome of the Section 508 review.